M De Laurentiis
Overview
Explore the profile of M De Laurentiis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blondeaux E, Boni L, Chila G, Dri A, Caputo R, Poggio F, et al.
ESMO Open
. 2025 Jan;
10(2):104125.
PMID: 39842245
Background: Estimating patient attrition across lines of treatment (i.e. the probability that upon treatment failure the patient will not be able to receive a subsequent treatment) may be a valuable...
2.
Gravina A, Gargiulo P, De Laurentiis M, Arenare L, De Placido S, Orditura M, et al.
ESMO Open
. 2025 Jan;
10(1):104085.
PMID: 39754976
Background: The Hormonal Bone Effects (HOBOE) study tested whether adjuvant triptorelin plus either letrozole (L) or zoledronic acid (Z) plus L (ZL) was more effective than tamoxifen (T) in premenopausal...
3.
Poggio F, Blondeaux E, Tagliamento M, Perachino M, Nardin S, Conte B, et al.
ESMO Open
. 2024 Aug;
9(8):103650.
PMID: 39121814
Background: The phase III GIM2 trial showed improved disease-free survival (DFS) and overall survival (OS) with adjuvant dose-dense (DD) as compared with standard-interval (SI) chemotherapy in women with node-positive early-stage...
4.
Calabrese A, von Arx C, Tafuti A, Pensabene M, De Laurentiis M
Cancer Treat Rev
. 2024 Jun;
129:102785.
PMID: 38870570
The detection of germline pathogenic variants (gPVs) in BRCA1/2 and other breast cancer (BC) genes is rising exponentially thanks to the advent of multi-gene panel testing. This promising technology, coupled...
5.
Fassio A, Porciello G, Carioli G, Palumbo E, Vitale S, Luongo A, et al.
Reumatismo
. 2024 Mar;
76(1).
PMID: 38523582
Objective: To report cross-sectionally serum levels of 25-hydroxyvitamin D [25(OH)D] in women living in Italy within 12 months from breast cancer (BC) diagnosis. Methods: Baseline data were obtained from 394...
6.
Pensabene M, Calabrese A, von Arx C, Caputo R, De Laurentiis M
Cancer Treat Rev
. 2024 Mar;
125:102702.
PMID: 38452709
A relevant percentage of breast cancers (BCs) are tied to pathogenetic (P)/likely pathogenetic (LP) variants in predisposing genes. The knowledge of P/LP variants is an essential element in the management...
7.
Rizzo A, Schipilliti F, Di Costanzo F, Acquafredda S, Arpino G, Puglisi F, et al.
ESMO Open
. 2023 Dec;
8(6):102198.
PMID: 38100933
Background: The use of combination of chemotherapy with immune checkpoint inhibitors (ICIs) has shown efficacy in triple-negative breast cancer (TNBC), and chemoimmunotherapy has been introduced in clinical practice. However, limited...
8.
Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al.
Breast Cancer Res
. 2023 Aug;
25(1):103.
PMID: 37653397
Background: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor-positive,...
9.
Miglietta F, Fabi A, Generali D, Dieci M, Arpino G, Bianchini G, et al.
Cancer Treat Rev
. 2023 Jul;
119:102594.
PMID: 37400291
No abstract available.
10.
Di Lauro V, Barchiesi G, Martorana F, Zucchini G, Muratore M, Fontanella C, et al.
ESMO Open
. 2022 Nov;
7(6):100629.
PMID: 36399953
Background: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed...